Qtron Investments LLC Grows Stake in Eli Lilly and Company $LLY

Key Points

• Qtron Investments LLC increased its holdings in Eli Lilly and Company by 9.2%, owning 9,832 shares valued at approximately $8.12 million by the end of the last quarter.
• Several other institutional investors, like Hobbs Wealth Management and O'Brien Wealth Partners, also boosted their stakes in Eli Lilly during the first quarter, with hedge funds holding 82.53% of the company’s stock.
• In recent analyst ratings, targets for Eli Lilly's stock have been lowered by multiple firms, with the average price target currently at $950.17 amid a mix of ratings from sell to strong buy.

Qtron Investments LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,832 shares of the company's stock after buying an additional 826 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of Qtron Investments LLC's investment portfolio, making the stock its 14th biggest holding. Qtron Investments LLC's holdings in Eli Lilly and Company were worth $8,120,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Knightsbridge Asset Management LLC lifted its stake in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after buying an additional 15 shares in the last quarter. Corient IA LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $570,000. LS Investment Advisors LLC lifted its position in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after acquiring an additional 40 shares in the last quarter. Prism Advisors Inc. acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $207,000. Finally, CSM Advisors LLC boosted its stake in Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after purchasing an additional 245 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent research reports. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $950.17.

Insider Activity

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $5.5170 on Tuesday, reaching $703.5670. 5,929,987 shares of the company traded hands, compared to its average volume of 6,686,759. The company has a 50 day moving average of $760.97 and a 200 day moving average of $793.02. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53. The firm has a market capitalization of $665.90 billion, a PE ratio of 45.98, a PEG ratio of 0.97 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. Eli Lilly and Company's payout ratio is presently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.